We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » 'INTRUSIVE' COMMITTEE MEMBER DISCLOSURE POLICY INSURES OBJECTIVITY
'INTRUSIVE' COMMITTEE MEMBER DISCLOSURE POLICY INSURES OBJECTIVITY
January 28, 2004
While the majority of new drug applications never see the light of an FDA advisory committee, those that do certainly get their share of publicity and public scrutiny -- factors the agency's senior official in charge of advisory committees welcomes when the agency is faced with approving a controversial new drug.